Immuno-PCR-based quantification of multiple phosphorylated tau-epitopes linked to Alzheimer’s disease

Singer, David; Soininen, Hilkka; Alafuzoff, Irina; Hoffmann, Ralf
December 2009
Analytical & Bioanalytical Chemistry;Dec2009, Vol. 395 Issue 7, p2263
Academic Journal
Several lines of evidence suggest that quantification of phosphorylated sites in the tau-protein (phospho-τ) might be favorable for early and specific Alzheimer’s disease diagnosis. The typical setup to quantify phosphorylated τ-epitopes relies on a sandwich ELISA with a capture antibody (Ab) recognizing τ independent of its phosphorylation status and a detector Ab binding specifically to a certain phosphorylation site. Besides Ab specificities, major challenges arise from the very low τ-concentrations in cerebrospinal fluid (CSF) ranging from 100 to 2,000 pg/ml. Based on the phosphorylation degree of a given position, which can be below 10%, the corresponding phospho-τ-level might be much lower, especially for multiphosphorylated epitopes studied here. Thus, a novel, highly sensitive, and generally applicable immunoassay is described to quantify τ-versions, which are phosphorylated at pThr212/pSer214/pThr231/pSer235, down to τ-concentrations of 2 pg/ml in CSF.


Related Articles

  • A Luminex Assay Detects Amyloid β Oligomers in Alzheimer’s Disease Cerebrospinal Fluid. Herskovits, Adrianna Z.; Locascio, Joseph J.; Peskind, Elaine R.; Li, Ge; Hyman, Bradley T. // PLoS ONE;Jul2013, Vol. 8 Issue 7, p1 

    Amyloid beta (aβ) protein assembles into larger protein aggregates during the pathogenesis of Alzheimer’s disease (AD) and there is increasing evidence that soluble aβ oligomers are a critical pathologic species. Diagnostic evaluations rely on the measurement of increased tau and...

  • Immunological indices in the cerebrospinal fluid of patients with presenile dementia of the Alzheimer type. Jonker, C.; Eikelenboom, P.; Tavenier, P. // British Journal of Psychiatry;Jan82, Vol. 140, p44 

    In ten patients with presenile dementia of the Alzheimer type and in a control group the levels of the different immunoglobulins were determined in both serum and cerebrospinal fluid (CSF), and gel electrophoretic techniques used to determine possible oligoclonal bands in the gamma-globulin...

  • Causes and Diagnosis of Alzheimer's Disease: A Proteomics Approach. Poljak, Anne; Sachdev, Perminder; Smythe, George A. // Current Proteomics;Jul2006, Vol. 3 Issue 2, p81 

    Proteomics has become a powerful tool facilitating hypothesis-driven exploration of disease states as well as offering a global approach which can uncover potentially important, though unexpected links to disease etiology. Despite many recent advances, the pathophysiological basis of Alzheimer's...

  • Spinal fluid test a 'real weapon' against Alzheimer's.  // Therapy Today;Jul2011, Vol. 22 Issue 6, p6 

    No abstract available.

  • Quantification of clusterin in paired cerebrospinal fluid and plasma samples. Jongbloed, Wesley; Herrebout, Maaike AC; Blankenstein, Marinus A; Veerhuis, Robert // Annals of Clinical Biochemistry;Sep2014, Vol. 51 Issue 5, p557 

    The article discusses the quantification of clusterin (ApoJ) in paired plasma and cerebrospinal fluid (CSF) in patients with Alzheimer's disease (AD). The role of clustering in Alzheimer's disease (AD) pathology is discussed. Four different antibodies in their ability to detect recombinant...

  • Immune complexes of auto-antibodies against Aβ1-42 peptides patrol cerebrospinal fluid of non-Alzheimer's patients. Henkel, A. W.; Dittrich, P. S.; Groemer, T. W.; Lemke, E. A.; Klingauf, J.; Klafki, H. W.; Lewczuk, P.; Esselmann, H.; Schwille, P.; Kornhuber, J.; Wiltfang, J. // Molecular Psychiatry;Jun2007, Vol. 12 Issue 6, p601 

    The diagnostic potential of large Aβ-peptide binding particles (LAPs) in the cerebrospinal fluid (CSF) of Alzheimer's dementia (AD) patients and non-AD controls (nAD) was evaluated. LAPs were detected by confocal spectroscopy in both groups with high inter-individual variation in number....

  • Effects of Cholinesterase Inhibitors on the Activities and Protein Levels of Cholinesterases in the Cerebrospinal Fluid of Patients with Alzheimer's Disease: A Review of Recent Clinical Studies. Darreh-Shori, T.; Soininen, H. // Current Alzheimer Research;Jan2010, Vol. 7 Issue 1, p67 

    Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by cognitive decline associated with a deficit in cholinergic function. Inhibitors of acetylcholinesterase (AChE) and/or butyrylcholinesterase (BuChE), such as donepezil, galantamine or rivastigmine, are widely...

  • Normal pressure hydrocephalus. Anderson, Milne // British Medical Journal (Clinical Research Edition);10/4/1986, Vol. 293 Issue 6551, p837 

    Focuses on the normal pressure hydrocephalus. Difficulty of selecting patients to benefit shunt procedures; Proposition to carry out a cerebrospinal fluid diversionary procedure; Changes in Alzheimer's disease.

  • Proteomic Analysis of Alzheimer's Disease Cerebrospinal Fluid from Neuropathologically Diagnosed Subjects. Maarouf, Chera L.; Andacht, Tracy M.; Kokjohn, Tyler A.; Casta�o, Eduardo M.; Sue, Lucia I.; Beach, Thomas G.; Roher, Alex E. // Current Alzheimer Research;Aug2009, Vol. 6 Issue 4, p399 

    A crucial need exists for reliable Alzheimer's disease (AD) diagnostic and prognostic tests. Given its intimate communication with the brain, the cerebrospinal fluid (CSF) has been surveyed intensively for reliable AD biomarkers. The heterogeneity of AD pathology and the unavoidable difficulties...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics